PranaX Corporation Establishes Houston Headquarters at Levit Green, a Premier Life Science Campus
Houston, Texas – April 17, 2025 – PranaX Corporation, an emerging regenerative medicine biotechnology company, secured its manufacturing and development headquarters at Levit Green, a 53-acre life sciences-centric district in Houston, Texas. The company signed a lease for a 7,400-square-foot, turn-key lab space in the Phase I building of Levit Green, where it will establish its research and commercial operations.
Levit Green’s Phase I building is a cutting-edge research and office facility, expertly designed and engineered to support the development of innovative technologies, pharmaceuticals, and medical therapies. This state-of-the-art complex features a fully equipped conference center, a spacious fitness center, and a dedicated vivarium space, creating a self-contained environment that fosters collaboration, wellness, and groundbreaking research.
“Levit Green was purpose-built to the highest standards to meet the evolving demands of the life sciences sector, offering high-performance space designed for research and manufacturing. PranaX’s decision to locate here highlights the growing need for advanced environments that foster innovation,” said John Mooz, Senior Managing Director of Hines, developer of Levit Green. “Their presence strengthens the momentum of our growing life sciences community, and we’re excited to be part of their journey as they innovate and scale.”
At Levit Green, PranaX will develop the use of exosomes as therapeutics, physician-directed supplements, and wellness products that can promote healthy aging and combat chronic disease. PranaX’s expansion into Levit Green reinforces its commitment to pioneering advancements in the biotechnology industry, contributing to Texas’s growing efforts to establish itself as a leading hub for biopharmaceutical innovation. This presence aligns with the state’s vision to cultivate a thriving biotech ecosystem, particularly in Houston, which continues to attract leading companies and research institutions. With a focus on scientific excellence, technological innovation, and commercialization, PranaX is excited to shape the future of regenerative medicine as a part of the Houston biotech community.
PranaX recently entered into a technology licensing agreement with The University of Texas MD Anderson Cancer Center that will allow the development of exosome products to combat the decline in quality of life associated with aging, inflammation, and tissue damage. Located in Houston, adjacent to the Texas Medical Center, the company’s headquarters features a Good Manufacturing Practice facility designed to streamline the transfer of MD Anderson’s exosome manufacturing technology, enabling commercial and clinical stem cell exosome products. For more details see PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes.
“We are thrilled to join the vibrant life science community at Levit Green,” said Lance Kelly, Director of Commercialization at PranaX. “This facility will enable us to explore exosome research and product development to continually generate solutions that enhance the quality of life.”
About PranaX Corporation
PranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell-derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs through evidence-based science. The company’s overarching mission is to unlock the regenerative properties of exosomes to promote wellness, combat chronic disease, and lead individuals toward healthier, more fulfilling lives. For more information, see www.pranax.com.
Contact:
Lance Kelly
800-507-5581
PranaX Licenses Exosome Technology to Commercialize Stem Cell Exosomes
Houston, Texas – March 13, 2025 – PranaX Corporation (www.pranax.com), an emerging regenerative medicine biotechnology company, today announced that it has licensed exosome technology from The University of Texas MD Anderson Cancer Center to develop exosomes for use as commercial and clinical products to combat the decline in quality of life associated with aging, inflammation, and tissue damage.
The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This agreement will allow PranaX to commercialize the use of exosomes as therapeutics, physician-directed supplements, and wellness products that can promote healthy aging and combat chronic disease. PranaX will combine in-house regenerative medicine technology with MD Anderson’s clinical exosomes knowledgebase to advance exosomes in regenerative medicine through evidence-based science. The licensed technology was part of the first FDA approved trial to test mesenchymal stem cell derived exosomes in cancer patients.
The company’s first commercial product, ExoWELL™, is a physician-directed, GMP stem cell exosome supplement for application in health and wellness. It has the potential to modulate cellular function and promote tissue regeneration. “We are thrilled to have secured a license for these technologies, empowering us to develop and advance our commercial exosome product line” said Phillip Maderia, CEO of PranaX Corporation.” This technology holds the promise of revolutionizing the treatment of age-related conditions in humans.”
Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX, “This is an amazing opportunity to harness best-in-class technology that has been tested in the clinic through Phase I safety studies.” says Dr. Greco, “PranaX intends to expand these data to enhance quality of life during the later stages of adulthood.”
Under the terms of the agreement, MD Anderson will license stem cell exosome manufacturing technology, used in its Phase I study targeting KRASG12D in pancreatic cancer (https://www.medrxiv.org/content/10.1101/2025.03.03.25322827v1), to PranaX to launch their ExoWELL™ platform. Other licensed technology allows PranaX to develop several clinical programs for non-cancer indications, specifically for age-related chronic diseases.
PranaX’s Houston-based headquarters features a GMP-compliant facility designed to streamline the transfer of MD Anderson’s exosome manufacturing technology, enabling the production of both commercial and clinical stem cell exosome products. Additionally, PranaX will utilize the facility to offer exosome banking services, under its ExoSTORE™ brand, which will offer personalized collection and banking of exosomes from peripheral blood, umbilical cord blood, and neonatal tissues.
“As medical expenses rise and relative health quality remains stagnant, it becomes ever more important to prioritize long-term health and well-being.” said Dr. Greco. “We believe this agreement will allow us to make a difference in improving individuals’ livelihoods along a health span vs. lifespan continuum.”
About PranaX Corporation
PranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell-derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs through evidence-based science. The company’s overarching mission is to unlock the regenerative properties of exosomes to promote wellness, combat chronic disease, and lead individuals towards healthier, more fulfilling lives. The company’s research, development, and manufacturing operations are headquartered within the Levit Green life science campus in Houston, Texas.
Contact:
Lance Kelly
800-507-5581
PranaX Appoints Phillip Maderia as CEO to Lead Exosome Innovation
Houston, Texas – March 12, 2025 – PranaX Corporation, a pioneer in exosome-based regenerative wellness, proudly announces the appointment of Phillip Maderia as its new Chief Executive Officer. With over three decades of leadership in biopharmaceutical manufacturing, most notably in pioneering exosome production, Phillip brings unparalleled expertise to advance PranaX’s mission of leveraging exosomes to enhance quality of life nationwide.
PranaX is committed to harnessing the evolving biology of exosomes, nature’s cellular messengers, to confer regenerative properties on aging, inflamed, and damaged tissues and organs. The company aims to develop exosomes as natural physician-directed supplements and wellness products, delivering transformative health benefits globally.
Phillip joins PranaX from Lonza, where he served as Site Head and exosome Business Leader of the Lexington, MA, manufacturing facility since 2021. At Lonza, he spearheaded the expansion of the exosome business, overseeing a $12M operation and leading the construction of Lonza’s first 500L-scale GMP exosome manufacturing process. His strategic vision was instrumental in Lonza’s acquisition of Codiak BioSciences’ intellectual property and clinical programs in 2023, cementing the company’s leadership in the exosome field. Before Lonza, Phillip served as VP Manufacturing Operations at Codiak BioSciences where he led the supply of three exosome clinical programs in oncology, and at LFB-USA and Sanofi Genzyme, where he held senior roles in manufacturing and engineering leadership in biologics manufacturing.
“Phillip’s exceptional track record in exosome and biologics manufacturing and his ability to translate complex science into impactful solutions make him the perfect leader for PranaX,” said Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX. “His arrival marks a defining moment as we accelerate our journey to bring exosome-based wellness products to the world.”
“I’m thrilled to lead PranaX at this exciting juncture,” said Phillip. “Exosomes represent a frontier in regenerative wellness, and PranaX’s mission to make these benefits widely accessible resonates deeply with me. I look forward to driving our team to deliver natural, science-driven products that empower people to live healthier, more vibrant lives.”
Under Phillip’s leadership, PranaX aims to expand its research pipeline, forge strategic partnerships, and bring its innovative exosome solutions to market, solidifying its role as a global leader in next-generation wellness.
About PranaX Corporation
PranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell- derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs through evidence-based science. The company’s overarching mission is to unlock the regenerative properties of exosomes to promote wellness, combat chronic disease, and lead individuals towards healthier, more fulfilling lives. The company’s research, development, and manufacturing operations are headquartered within the Levit Green life science campus in Houston, Texas.
Contact:
Lance Kelly
Press@pranax.com
800-507-5581
PranaX: Diamond Sponsor at the 2023 AAEV Conference Boston
AAEV promotes the development, dissemination, integration, and utilization of knowledge in the field of extracellular vesicles.
May 19, 2024
(HOUSTON) – We are proud to reflect on our role as a Diamond Sponsor for the American Association of Extracellular Vesicles (AAEV) conference, which took place in Boston, Massachusetts from October 27-29, 2023. This prestigious event was dedicated to the advancement of knowledge in the field of extracellular vesicles, promoting their development, dissemination, integration, and utilization across various scientific and medical disciplines.
Extracellular vesicles are small particles released by cells that play crucial roles in intercellular communication, disease mechanisms, and potential therapeutic applications. The AAEV is at the forefront of fostering research and innovation in this rapidly evolving field, bringing together experts and enthusiasts to share groundbreaking findings and collaborate on future initiatives.
The 2023 AAEV Annual Meeting was a remarkable gathering of esteemed professionals from around the world. Attendees engaged in in-depth discussions and presentations on the latest discoveries and technological advancements related to extracellular vesicles. The conference provided a platform for networking, collaboration, and the exchange of ideas.
We were honored that PranaX scientific co-founders, Dr. Raghu Kalluri, MD/PhD and Dr. Valerie LeBleu, MD/PhD, MBA, actively participated in the conference. Dr. Kalluri, who served on the organizing committee and is the current president of the AAEV, brought a wealth of knowledge and leadership to the event. Alongside him, Dr. LeBleu, a distinguished scientist in the field, shared her
insights and research findings with attendees. As a leader in the biotech industry, PranaX is committed to pioneering advancements in EV research and technology. Our sponsorship of the AAEV conference underscored our dedication to supporting the
scientific community and contributing to the collective understanding of extracellular vesicles.
Reflecting on our participation in the 2023 AAEV conference, we are more motivated than ever to continue our work in the field of extracellular vesicles. This event was an invaluable opportunity for learning, networking, and advancing the science of extracellular vesicles. We look forward to supporting and participating in the next AAEV conference this November 2024 in Houston, Texas, where PranaX’s own Dr. Valerie LeBleu, MD/PhD, MBA, will serve as a co-chair. We’re excited to continue contributing to the remarkable work being done in this field.
Together, let’s push the boundaries of science and unlock the full potential of extracellular vesicles.
The Power of Exosomes and Healthy Aging
Exploring the Transformative Potential of Exosomes in Aging and Regenerative Medicine
May 8, 2024
In today’s rapidly evolving world of biotechnology, the quest for wellness, regenerative healing, and innovative advancements in healthcare has never been more pressing. At PranaX, we stand at the forefront of this scientific frontier, dedicated to extending one’s healthspan, enhancing quality of life, and redefining the boundaries of modern medicine.
Our journey begins with a profound understanding of the intricate biology that governs life itself. From the cellular level to the complexities of aging and disease, we delve deep into the very essence of existence. The causes of aging are complex and overlapping, with the primary hallmarks of aging including genomic instability, telomere erosion, epigenetic alteration, and defective protein homeostasis, termed proteostasis.
Through relentless research and groundbreaking technology, we unlock the potential of exosomes – nature’s own messengers of healing and rejuvenation. Exosomes are nanosized extracellular vesicles (EVs) secreted by cells, which hold immense promise in the field of regenerative medicine. Studies into the role of EVs during aging have demonstrated their ability to modulate aging-related phenotypes and in pro-rejuvenation therapies, with the potential to benefit many diseases associated with aging.
At PranaX, we harness the therapeutic potential of exosomes to drive clinical innovation and redefine the future of healthcare. From combating age-related diseases to rejuvenating aging organs, our pioneering therapies aim to restore health and vitality at its core. Through cutting-edge stem cell technology, we unlock the body’s innate ability to heal and thrive, offering a natural alternative to traditional interventions.
But our vision extends beyond mere treatment – it encompasses a holistic approach to well-being and preventative care. By banking on the science of longevity and harnessing the body’s innate regenerative capacity, we empower individuals to take control of their healthspan through bio-insurance.
Join us as we embark on this transformative journey towards a future where health knows no age, diseases are conquered, and every individual has the opportunity to thrive. Together, let us unlock the secrets of life, elevate the standard of care, and pave the way for a healthier, happier tomorrow.
American Association of Extracellular Vesicles – Houston, TX | November 10-13
Save the Date: November 10-13, 2024
The 2nd AAEV meeting invites scientists from academia and industry! AAEV promotes the development, dissemination, integration, and utilization of knowledge in the field of extracellular vesicles (EV). The Association provides a platform for researchers to learn, disseminate, and network with EV researchers worldwide through Annual Conferences, peer-reviewed journal, initiatives, and industry partnerships.
Hines Signs PranaX To Levit Green, Houston’s Premier Life Science Campus
Regenerative Science Biotech Firm Secures State-of-the-Art, Ready-to-Occupy Laboratory
(HOUSTON) – Hines, the global real estate investment manager, in partnership with 2ML Real Estate Interests and Harrison Street, today announced the next lease at Levit Green, the 53-acre mixed-use life sciences-centric district adjacent to the Texas Medical Center in Houston, Texas. PranaX, a pioneering company in regenerative science, has leased a 7,400-square-foot, turn-key lab space on the second floor of Levit Green’s Phase I building. PranaX will be moving into its new space this week, showcasing the truly move-in-ready nature of the space.
“PranaX’s groundbreaking work represents exactly the kind of innovation and collaboration that Levit Green was designed to foster,” said John Mooz, senior managing director at Hines. “We recognized the need in the market to provide immediate, state-of-the-art research facilities and look forward to supporting PranaX in their mission to manufacture regenerative therapies.”
PranaX is an emerging biotechnology company dedicated to harnessing exosomes to rejuvenate aging, inflamed, and damaged tissues and organs. The company’s goal is to unlock the regenerative properties of exosomes to enhance quality of life, contributing to healthier, more fulfilling lives. PranaX has entered into a technology licensing agreement with The University of Texas MD Anderson Cancer Center and aims to utilize this technology to commercialize exosomes as therapeutics, natural supplements and wellness products that can promote healthy aging. The company’s research and development and manufacturing operations will be headquartered in Houston, within Levit Green.
“We are incredibly excited to establish our research and commercial operations within the world-class facility built by Hines at Levit Green, said Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX. “This is an amazing opportunity to retain technology developed locally and expand upon it within the Houston biotech ecosystem.”
In collaboration with Hines, PranaX is now building a ISO-7 clean room that meets FDA standards. This clean room will be instrumental in manufacturing approved therapies for patients at their offsite clinic, further enhancing the suite’s capabilities to support cutting-edge research and development. Additionally, PranaX will utilize the suite to offer exosome banking services, an innovative approach to support wound healing and initiate cell growth and development. This service aligns with the growing interest in personalized medicine and the potential for clinical breakthroughs in the treatment of serious medical conditions.
Dr. Stan Watowich, the founder and CEO of nearby Ridgeline Therapeutics, commented on Levit Green’s transformative potential at a recent Greater Houston Partnership event, saying, “I view Levit Green as Houston’s newest cathedral for biomedical innovation, a destination where visionary biotech companies will receive inspiration, collaboration and support as they continue their quest to bring life-changing healthcare technologies to patients.”
Completed in 2023, Levit Green’s first phase is a state-of-the-art lab, biomanufacturing facility designed with flexibility in mind to meet the evolving needs of the life sciences industry. The 290,000-square-foot, five-story building is part of the broader nine-building Levit Green masterplan, which will offer a curated mix of research and production facilities, office, retail, residential, and outdoor amenities. The building has two turnkey laboratory suites, each approximately 11,000 square feet, available for immediate occupancy and leasing. These suites come fully equipped with lab benching, casework, and furniture, offering a ready-to-use space for scientific research. Additionally, the building features 25,000 square feet of dedicated lab incubator space, designed to support entrepreneurs and early-stage life science companies. This space not only provides top-tier laboratory and office facilities in a strategic location but also fosters networking opportunities for burgeoning businesses in the life sciences sector.
For more information visit levitgreen.com